STAT+: BeOne wins FDA approval in lymphoma race
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- CREATE Medicines raised $122 million to advance its in‑vivo CAR‑T therapy for autoimmune disease into the clinic.
- Trump administration is searching for a new FDA commissioner, sparking a politically fraught fight over the agency’s future direction.
- STAT+ provides exclusive articles to subscribers, highlighting the intersection of biotech innovation and regulatory politics.
Why it matters: Investors in biotech stand to benefit from CREATE Medicines’ $122 M raise, while the Trump administration’s FDA commissioner search reshapes drug‑approval timelines, affecting patients awaiting new therapies.
